Back to top
more

Roka Bioscience, Inc. (ROKA)

(Real Time Quote from BATS)

$0.65 USD

0.65
NA

-0.02 (-2.97%)

Updated Dec 28, 2017 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[ROKA]

Reports for Purchase

Showing records 1 - 13 ( 13 total )

Industry: Medical - Instruments

Record: 1

04/18/2017

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ROKA

Provider: ValuEngine, Inc

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 2

01/17/2017

Company Report

Pages: 4

We are transferring coverage of ROKA to ROTH Capital Research, due to the departure of the covering analyst

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 3

01/17/2017

Daily Note

Pages: 2

Consumer - Coverage Update - Consumer

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 4

12/12/2016

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 5

12/12/2016

Company Report

Pages: 18

We are initiating coverage of Roka with a Buy rating and a 12-month price target of $10.

Provider: Roth Capital Partners, Inc.

Analyst: BRENNER A

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 6

10/07/2016

Company Report

Pages: 5

Dropping Coverage Due to Analyst Departure

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 7

11/12/2015

Company Report

Pages: 10

3Q15 Recap - Progress Slow - Revamped Listeria Test Launched - Maintain NEUTRAL - Lowering PT from $3 to $2

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 8

08/14/2015

Company Report

Pages: 10

2Q15 Top-line Stable - System Placements Lackluster - Opex Ok - On Track for Listeria Relaunch in 2H15 - No Pipeline Color - Maintain N - PT to $3

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 9

08/13/2015

Industry Report

Pages: 17

HEALTHCARE: 2015 Wedbush PacGrow Healthcare Conference Day 2

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 10

05/08/2015

Company Report

Pages: 10

1Q15 Recap - Results In-Line with Street - Below Wedbush - Slight Improvement in Systems Sales - Cutting Estimates - Lowering PT to $3.50 - Maintain N

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 11

11/06/2014

Company Report

Pages: 9

Downgrading ROKA to NEUTRAL on Unexpected Listeria Product Issues and a More Onerous Sales Cycle - Lowering PT to $9 from $15

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 12

08/12/2014

Company Report

Pages: 9

2Q14 Results Consistent with Our Initiation -- Revenue Estimates Unchanged -- Pipeline Roughly On Track -- Maintain OP

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 13

08/10/2014

Company Report

Pages: 21

Initiating Coverage with an OUTPERFORM Rating & $15 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 75.00

Research Provided by a Third Party
// eof